mona said elzoghbi

Prof. mona said elzoghbi

Menoufia University, Shibīn al Kawm, Al Minūfīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAmr K.A. Bass
Amr K.A. Bass
mona said elzoghbimona said elzoghbi
mona said elzoghbi
ENEl-Shimaa M. Nageeb
El-Shimaa M. Nageeb
MMMamdouh F. A. Mohamed
Mamdouh F. A. Mohamed
MBMohamed Badr
Mohamed Badr
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma

12 February 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
mona said elzoghbimona said elzoghbi
mona said elzoghbi
SESamiha A. El-Sebaey
Samiha A. El-Sebaey
HAHanan A. Al-Ghulikah
Hanan A. Al-Ghulikah
ESEman A. Sobh
Eman A. Sobh
New thiazolopyrimidine derivatives 2, 3a-d, 4a-c, 5, 6a-c, and 7a,b were synthesised. All prepared compounds were evaluated by MTT cytotoxicity assay against three human tumour cell lines. Compounds 3c, 3d, 4c, 6a, 6b, and 7b exhibited potent to strong anticancer activity that was nearly comparable or superior to Doxorubicin. Compounds exhibiting significant cytotoxicity were further selected to study their inhibitory activity on the Topo II enzyme. Compound 4c was the most potent Topo II inhibitor with an IC50 value of 0.23 ± 0.01 µM, which was 1.4-fold and 3.6-fold higher than the IC50 values of Etoposide and Doxorubicin. Furthermore, compound 4c showed significant cell cycle disruption and apoptosis on A549 cells compared to control cells. Molecular docking of the most active compounds illustrated proper fitting to the Topo II active site, suggesting that our designed compounds are promising candidates for the development of effective anticancer agents acting through Topo II inhibition. Graphical Abstract

2 November 2022 in Molecules
Verified
Journal Article
Open access
PDF file
HAHanan Al-Ghulikah
Hanan Al-Ghulikah
SESamiha A. El-Sebaey
Samiha A. El-Sebaey
ABAmr K. A. Bass
Amr K. A. Bass
mona said elzoghbimona said elzoghbi
mona said elzoghbi
Two series of cyanopyrimidine hybrids were synthesized bearing either benzo[d]imidazole, benzo[d]oxazole, benzo[d]thiazole, and benzo[b]thiophene derivatives via methylene amino linker 3a–3d (Formula A) or various sulphonamide phenyl moieties 5a–5d (Formula B) at the C-2 position. All compounds’ cyclooxygenase COX-2 inhibitory activities were evaluated, and all synthesized compounds demonstrated potent activity at minimal concentrations, with IC50 values in the submicromolar range. Compounds 3b, 5b, and 5d were discovered to be the most active pyrimidine derivatives, with the highest COX-2 percent inhibition and IC50 values being nearly equal to Celecoxib and approximately 4.7-, 9.3-, and 10.5-fold higher than Nimesulide. Furthermore, the pyrimidine derivatives 3b, 5b, and 5d demonstrated anticancer activity comparable to or better than doxorubicin against four cell lines, i.e., MCF-7, A549, A498, and HepG2, with IC50 values in nanomolar in addition to low cytotoxicity on the normal W38-I cell line. The effect of compound 5d on cell cycle progression and apoptosis induction was investigated, and it was found that compound 5d could seize cell growth at the sub-G1 and G2/M phases, as well as increase the proportion of early and late apoptotic rates in MCF-7 cells by nearly 13- and 60-fold, respectively. Moreover, in silico studies for compounds 3b, 5b, and 5d revealed promising findings, such as strong GIT absorption, absence of BBB permeability, nil-to-low drug–drug interactions, good oral bioavailability, and optimal physicochemical properties, indicating their potential as promising therapeutic candidates.

1 July 2023 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
EHEbtehal Mohammed Husseiny
Ebtehal Mohammed Husseiny
Hamada S. AbulkhairHamada S. Abulkhair
Hamada S. Abulkhair
SESanadelaslam Sa El-Hddad
Sanadelaslam Sa El-Hddad
NONada Osama
Nada Osama
mona said elzoghbimona said elzoghbi
mona said elzoghbi
Aim: A fragment-based design and synthesis of three novel series of aminopyridone-linked benzimidazoles as potential anticancer candidates with significant CDK9 inhibition was implemented. Material...

4 March 2024 in Future Medicinal Chemistry
Verified
Journal Article
Open access
mona said elzoghbimona said elzoghbi
mona said elzoghbi
ABAmr Ka Bass
Amr Ka Bass
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma
MMMamdouh F. A. Mohamed
Mamdouh F. A. Mohamed
MBMohamed Badr
Mohamed Badr
EAElshimaa Abdelhafez
Elshimaa Abdelhafez
Aim: The purpose of this work is to create and synthesize a new class of chemicals: 3-cyano-2-substituted pyridine compounds with expected multitarget inhibition of histone deacetylase (HDAC) and t... Graphical abstract

15 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SESamar El-Kalyoubi
Samar El-Kalyoubi
SESamiha A. El-Sebaey
Samiha A. El-Sebaey
SESherin M. Elfeky
Sherin M. Elfeky
HAHanan Al-Ghulikah
Hanan Al-Ghulikah
mona said elzoghbimona said elzoghbi
mona said elzoghbi
Structural-based drug design and solvent-free synthesis were combined to obtain three novel series of 5-arylethylidene-aminopyrimidine-2,4-diones (4, 5a–c, 6a,b), 5-arylethylidene-amino-2-thiopyrimidine-4-ones (7,8), and 6-arylpteridines (9,10) as dual BRD4 and PLK1 inhibitors. MTT assays of synthesized compounds against breast (MDA-MB-231), colorectal (HT-29), and renal (U-937) cancer cells showed excellent-to-good cytotoxic activity, compared to Methotrexate; MDA-MB-231 were the most sensitive cancer cells. The most active compounds were tested against normal Vero cells. Compounds 4 and 7 significantly inhibited BRD4 and PLK1, with IC50 values of 0.029, 0.042 µM, and 0.094, 0.02 µM, respectively, which are nearly comparable to volasertib (IC50 = 0.017 and 0.025 µM). Compound 7 triggered apoptosis and halted cell growth at the G2/M phase, similarly to volasertib. It also upregulated the BAX and caspase-3 markers while downregulating the Bcl-2 gene. Finally, active compounds fitted the volasertib binding site at BRD4 and PLK1 and showed ideal drug-like properties and pharmacokinetics, making them promising anticancer candidates.